| scholarly article | Q13442814 |
| P50 | author | Mario Venditti | Q88922328 |
| Marco Falcone | Q37831273 | ||
| Francesco Violi | Q37834358 | ||
| Federico Pea | Q38544304 | ||
| P2093 | author name string | Giuliana Lo Cascio | |
| Ido Iori | |||
| Ercole Concia | |||
| Antonino Mazzone | |||
| P2860 | cites work | Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease | Q28251330 |
| Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care | Q28251375 | ||
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
| Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome | Q28264458 | ||
| Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome | Q28276727 | ||
| Invasive aspergillosis in the intensive care unit | Q28306909 | ||
| Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy | Q28740362 | ||
| Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome | Q34036214 | ||
| Detection of Simulated Candidemia by the BACTEC 9240 System with Plus Aerobic/F and Anaerobic/F Blood Culture Bottles | Q40133371 | ||
| Detection of candidaemia in patients with and without underlying haematological disease. | Q40371873 | ||
| Fulminant invasive pulmonary aspergillosis in immunocompetent patients--a two-case report | Q40543559 | ||
| Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis | Q40734608 | ||
| Peripheral and total parenteral nutrition as the strongest risk factors for nosocomial candidemia in elderly patients: a matched case-control study | Q42263057 | ||
| Clinical experience of anidulafungin for the treatment of patients with documented candidemia. | Q42751895 | ||
| Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. | Q42947802 | ||
| Aspergillosis in "nonimmunocompromised" critically ill patients | Q43655100 | ||
| Management of central venous catheters in patients with cancer and candidemia | Q43877465 | ||
| Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy | Q44098424 | ||
| Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. | Q44318190 | ||
| Nosocomial bloodstream infections in United States hospitals: a three-year analysis | Q44863798 | ||
| Time to positivity of blood cultures of different Candida species causing fungaemia | Q45266692 | ||
| Candida infective endocarditis: report of 15 cases from a prospective multicenter study. | Q46013578 | ||
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. | Q47643534 | ||
| Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. | Q47799923 | ||
| Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience. | Q51000077 | ||
| Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. | Q51193935 | ||
| Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. | Q51746143 | ||
| Local resistance patterns to antimicrobials in internal medicine: a focused report from the REGIMEN (REGistro Infezioni in MEdicina INterna) study. | Q53120107 | ||
| Detection of sputum Aspergillus galactomannan for diagnosis of invasive pulmonary aspergillosis in haematological patients. | Q53746276 | ||
| Invasive Pulmonary Aspergillosis in Patients with Chronic Obstructive Pulmonary Disease: Report of Eight Cases and Review | Q57238104 | ||
| Galactomannan in Bronchoalveolar Lavage Fluid | Q57559940 | ||
| Combined detection of mannanaemia and anti-mannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species | Q59412889 | ||
| Infections Associated with Tumor Necrosis Factor-α Antagonists | Q59746724 | ||
| Comparison of clinical and post-mortem findings in intensive care unit patients | Q64126827 | ||
| Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis | Q79373822 | ||
| Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey | Q80052810 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| Towards an integral conceptual model of frailty | Q83073672 | ||
| Occurrence of influenza A(H1N1)v infection and concomitant invasive pulmonary aspergillosis in a patient with chronic obstructive pulmonary disease | Q84174531 | ||
| A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1→ 3)-β-d-g | Q84999464 | ||
| Candidemia subsequent to severe infection due to Clostridium difficile: is there a link? | Q86877713 | ||
| Conceptualisation and measurement of frailty in elderly people | Q34087251 | ||
| Caspofungin | Q34199905 | ||
| Ageing and infection | Q34984996 | ||
| The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy | Q35185757 | ||
| Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people | Q35363785 | ||
| Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients | Q35552743 | ||
| The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia | Q35561242 | ||
| Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. | Q35668212 | ||
| Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index | Q35908296 | ||
| Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis | Q35908313 | ||
| Serious infections in elderly patients with diabetes mellitus | Q36095855 | ||
| Current approaches to diagnosis and treatment of invasive aspergillosis | Q36357893 | ||
| Accurate and rapid identification of Candida spp. frequently associated with fungemia by using PCR and the microarray-based Prove-it Sepsis assay | Q36362975 | ||
| Micafungin: a new echinocandin | Q36436847 | ||
| Anidulafungin: a novel echinocandin | Q36508916 | ||
| Echinocandins for candidemia in adults without neutropenia | Q36593160 | ||
| Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths | Q36785939 | ||
| Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogr | Q37036246 | ||
| Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 | ||
| Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults | Q37450705 | ||
| Invasive aspergillosis in patients with liver disease | Q37812386 | ||
| Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia | Q37880471 | ||
| Diagnosing invasive fungal disease in critically ill patients | Q37900310 | ||
| Candidal thrombophlebitis of central veins: case report and review | Q37929789 | ||
| Invasive mycoses: diagnostic challenges | Q37971083 | ||
| Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. | Q37993043 | ||
| Pneumonia in frail older patients: an up to date | Q38017909 | ||
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. | Q38058556 | ||
| Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study | Q38570041 | ||
| P433 | issue | 5 | |
| P921 | main subject | internal medicine | Q11180 |
| invasive mycosis | Q112040879 | ||
| P304 | page(s) | 501-511 | |
| P577 | publication date | 2014-05-29 | |
| P1433 | published in | Internal and emergency medicine | Q26842320 |
| P1476 | title | Identification and management of invasive mycoses in internal medicine: a road-map for physicians | |
| P478 | volume | 9 |
| Q64135918 | A prediction rule for early recognition of patients with candidemia in Internal Medicine: results from an Italian, multicentric, case–control study |
| Q41706308 | Adherence to clinical practice guidelines for the treatment of candidemia at a Veterans Affairs Medical Center |
| Q33758772 | Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients |
| Q38694666 | Bloodstream infections in internal medicine. |
| Q89955684 | Candida bloodstream infection in patients with systemic autoimmune diseases |
| Q41031258 | Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment |
| Q89736946 | Do we need to adopt antifungal stewardship programmes? |
| Q41229223 | Epidemiological characteristics of bloodstream infections in patients with different degrees of liver disease. |
| Q40164347 | Pseudomembranous aspergillar tracheobronchitis in a non-neutropenic critically ill patient in the intensive care unit |
| Q38917135 | Targeting CYP51 for drug design by the contributions of molecular modeling. |
| Q91849961 | The glyoxylate cycle and alternative carbon metabolism as metabolic adaptation strategies of Candida glabrata: perspectives from Candida albicans and Saccharomyces cerevisiae |
Search more.